JP2019533646A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533646A5
JP2019533646A5 JP2019515636A JP2019515636A JP2019533646A5 JP 2019533646 A5 JP2019533646 A5 JP 2019533646A5 JP 2019515636 A JP2019515636 A JP 2019515636A JP 2019515636 A JP2019515636 A JP 2019515636A JP 2019533646 A5 JP2019533646 A5 JP 2019533646A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
seq
antibody
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515636A
Other languages
English (en)
Japanese (ja)
Other versions
JP6995844B2 (ja
JP2019533646A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052891 external-priority patent/WO2018057849A1/en
Publication of JP2019533646A publication Critical patent/JP2019533646A/ja
Publication of JP2019533646A5 publication Critical patent/JP2019533646A5/ja
Application granted granted Critical
Publication of JP6995844B2 publication Critical patent/JP6995844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515636A 2016-09-23 2017-09-22 アトピー性皮膚炎を治療するためのil-13アンタゴニストの使用 Active JP6995844B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662398713P 2016-09-23 2016-09-23
US62/398,713 2016-09-23
US201762527204P 2017-06-30 2017-06-30
US62/527,204 2017-06-30
US201762530683P 2017-07-10 2017-07-10
US62/530,683 2017-07-10
US201762539037P 2017-07-31 2017-07-31
US62/539,037 2017-07-31
PCT/US2017/052891 WO2018057849A1 (en) 2016-09-23 2017-09-22 Uses of il-13 antagonists for treating atopic dermatitis

Publications (3)

Publication Number Publication Date
JP2019533646A JP2019533646A (ja) 2019-11-21
JP2019533646A5 true JP2019533646A5 (enExample) 2020-10-22
JP6995844B2 JP6995844B2 (ja) 2022-02-04

Family

ID=60020628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515636A Active JP6995844B2 (ja) 2016-09-23 2017-09-22 アトピー性皮膚炎を治療するためのil-13アンタゴニストの使用

Country Status (28)

Country Link
US (3) US11434286B2 (enExample)
EP (2) EP3528838B1 (enExample)
JP (1) JP6995844B2 (enExample)
KR (1) KR102557643B1 (enExample)
CN (1) CN109715201A (enExample)
AU (1) AU2017330405B2 (enExample)
CA (1) CA3031589C (enExample)
CY (2) CY1126255T1 (enExample)
DK (1) DK3528838T5 (enExample)
ES (1) ES2958593T3 (enExample)
FI (2) FI3528838T3 (enExample)
FR (1) FR24C1017I2 (enExample)
HR (1) HRP20231015T1 (enExample)
HU (2) HUE063135T2 (enExample)
IL (1) IL265473B2 (enExample)
LT (2) LT3528838T (enExample)
MX (1) MX2019002672A (enExample)
NL (1) NL301269I2 (enExample)
NZ (1) NZ790629A (enExample)
PL (1) PL3528838T3 (enExample)
PT (1) PT3528838T (enExample)
RS (1) RS64550B1 (enExample)
RU (1) RU2752785C2 (enExample)
SG (1) SG11201900845YA (enExample)
SI (1) SI3528838T1 (enExample)
TW (1) TWI787203B (enExample)
UA (1) UA124269C2 (enExample)
WO (1) WO2018057849A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3448391T3 (fi) 2016-04-27 2024-06-19 Abbvie Mfg Management Unlimited Company Sellaisten sairauksien hoitomenetelmät, joissa IL-13-aktiviteetti on haitallinen, käyttämällä anti-IL-13-vasta-aineita
NZ790629A (en) * 2016-09-23 2025-11-28 Genentech Inc Uses of il-13 antagonists for treating atopic dermatitis
WO2021191220A1 (en) * 2020-03-23 2021-09-30 Medimmune Limited Methods for treating atopic dermatitis and related disorders
JP2021147383A (ja) * 2020-03-23 2021-09-27 メドイミューン・リミテッドMedImmune Limited アトピー性皮膚炎及び関連障害を処置するための方法
KR20230084166A (ko) * 2020-10-09 2023-06-12 쿄와 기린 가부시키가이샤 Ox40 관련 질환을 치료하는 방법
CA3208011A1 (en) * 2021-03-17 2022-09-22 Sarah Harris Methods of treating atopic dermatitis with anti il-13 antibodies
TWI847170B (zh) * 2021-07-16 2024-07-01 美商德米拉股份有限公司 用於治療異位性皮炎之il-13抗體
TWI859566B (zh) * 2021-08-13 2024-10-21 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
KR20250005040A (ko) * 2021-09-15 2025-01-09 더미라, 인코포레이티드 결절성 양진의 치료를 위한 il-13 억제제
AU2023265133A1 (en) * 2022-05-05 2024-11-21 Dermira, Inc. Il-13 antibodies for the treatment of atopic dermatitis
CA3252634A1 (en) 2022-06-17 2023-12-21 Apogee Therapeutics, Inc. ANTIBODIES BINDING TO INTERLEUKIN 13 AND METHODS OF USE
JP2025530181A (ja) * 2022-09-06 2025-09-11 アスラン ファーマシューティカルズ ピーティーイー リミテッド 皮膚炎患者における不眠または睡眠障害の治療
AU2024235509A1 (en) 2023-03-14 2025-09-18 Geovista Inc. Antibody specifically binding to interleukin-13, and use thereof
KR102773781B1 (ko) 2023-03-14 2025-02-28 주식회사 지오비스타 인터루킨-13에 특이적으로 결합하는 항체 및 그의 용도
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
KR20250017610A (ko) 2023-07-27 2025-02-04 김천균 아토피의 치료와 예방용 조성물 및 그 제조방법
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗il—13多特異性抗體構築體及其用途
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025155874A1 (en) * 2024-01-18 2025-07-24 Enveda Therapeutics, Inc. Methods and compounds for modulating immune response
WO2025264972A1 (en) * 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2025264960A1 (en) * 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
AU3369999A (en) 1998-04-02 1999-10-25 Genentech Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
CA2424602C (en) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
JPWO2003085119A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物のFcγ受容体IIIaに対する結合活性を高める方法
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
NO347530B1 (no) 2003-11-05 2023-12-11 Roche Glycart Ag Et humanisert type II anti-CD20 antistoff og vertscelle som produserer et humanisert type II anti-CD20 antistoff samt en fremgangsmåte for fremstilling og en farmasøytisk sammensetning.
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
CN1898264A (zh) * 2003-12-23 2007-01-17 泰勒公司 用新的抗il13单克隆抗体治疗癌症
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK1814615T3 (en) 2004-11-24 2016-01-11 Shl Group Ab Injection device
US7896850B2 (en) 2005-06-01 2011-03-01 Telefonaktiebolaget L M Ericsson (Publ) Device for delivering medicament
ES2314568T3 (es) 2005-06-01 2009-03-16 Shl Group Ab Dispositivo para la entrega de medicamento.
JP2009510046A (ja) 2005-09-30 2009-03-12 メドイミューン・リミテッド インターロイキン−13抗体組成物
KR20130020850A (ko) * 2005-10-21 2013-02-28 노파르티스 아게 Il-13에 대항한 인간 항체 및 치료적 용도
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
MX2009007406A (es) 2007-01-09 2010-01-25 Wyeth Corp Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
EP2652498B1 (en) 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
AU2013204900B2 (en) * 2010-12-16 2016-11-10 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
JP5814465B2 (ja) 2011-06-17 2015-11-17 エス・ホー・エル・グループ・アクチボラゲットShl Group Ab 注射装置
CA2839496C (en) 2011-06-17 2016-02-09 Shl Group Ab Injection device
SG11201401903PA (en) * 2011-10-31 2014-05-29 Genentech Inc Antibody formulations
ES2981062T3 (es) 2012-09-07 2024-10-07 Regeneron Pharma Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
KR20150139905A (ko) 2013-04-05 2015-12-14 제넨테크, 인크. 항-il-4 항체 및 이중특이적 항체 및 그의 용도
US20160363591A1 (en) * 2014-01-27 2016-12-15 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
WO2016149276A1 (en) 2015-03-16 2016-09-22 Genentech, Inc. Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
NZ790629A (en) * 2016-09-23 2025-11-28 Genentech Inc Uses of il-13 antagonists for treating atopic dermatitis

Similar Documents

Publication Publication Date Title
JP2019533646A5 (enExample)
RU2019103943A (ru) Применение антагонистов il-13 для лечения атопического дерматита
JP2019514974A5 (enExample)
JP2014240408A5 (enExample)
JP2016516016A5 (enExample)
CN114173816A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
JP2017160208A5 (enExample)
JP2022033891A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
JP2017534646A5 (enExample)
JP2018505882A5 (enExample)
JP2017537905A5 (enExample)
JP2015525798A5 (enExample)
FI4285929T3 (fi) Hbv:n yhdistelmähoito
RU2017120361A (ru) Антитела к pdgf-b и способы их применения
JP2016517421A5 (enExample)
IL310706A (en) Il-13 antibodies for the treatment of atopic dermatitis
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2017519799A5 (enExample)
JP2018535961A5 (enExample)
Chaplin et al. Plegridy for the treatment of RRMS in adults
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
IL316218A (en) Preparations and methods for treating eye diseases
NZ750179B2 (en) Uses of il-13 antagonists for treating atopic dermatitis
TH2001001181A (th) วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf
JPWO2023017252A5 (enExample)